Off-Target Effects, Durability and Long-Term Monitoring
What off-target edits, vector integration and delayed adverse events mean for gene therapy and gene editing, and how regulators and trials monitor patients for years after treatment.
Content last updated . This page has not been medically reviewed.
What "off-target" means
Genome editing tools such as CRISPR-Cas9 are directed to a chosen spot in DNA. MedlinePlus Genetics explains that a guide RNA recognizes the intended DNA sequence and the Cas9 enzyme cuts there. [1] "Off-target" means changes at places other than the intended one. A 2025 review states that substantial off-target genotoxicity concerns delay clinical translation, and that the absence of standardized guidelines leads to inconsistent practices across studies in how off-target effects are identified and measured. [2]Off-target is a laboratory and clinical safety concept. Detecting a possible off-target site in a lab test does not by itself show harm in a patient, and not detecting one does not prove none exist. For how the technology works, see gene editing and CRISPR explained.
How long are patients followed?
The FDA's guidance recommends that sponsors design long-term follow-up (LTFU) studies to collect data on delayed adverse events. [6] It states that in earlier guidance FDA advised observing subjects for as long as 15 years, and that the updated recommendations are risk based. [3] The guidance lists durations of up to 15 years for genome editing products and up to 5 years for AAV vectors. [3] It also says not all gene therapy products require LTFU, and that a risk assessment should be done by the sponsor. [6]For genome-editing products, the FDA separately issued guidance on information sponsors should provide on product design, manufacturing, nonclinical safety assessment and clinical trial design. [7]
People treated with Casgevy and Lyfgenia were to be followed in a long-term study, according to the FDA's approval announcement. [5]
What the trials reported
In the phase 3 trial of exa-cel (Casgevy) in sickle cell disease, 44 patients were treated with median follow-up of 19.3 months, and the authors reported no cancers. [8] That is promising but limited evidence on safety: the follow-up is far shorter than the monitoring period the FDA discusses.Questions to ask
- Is long-term follow-up part of the treatment plan, and for how long?
- What are the known delayed risks for this exact product?
- Could this product's risk differ from a similar-sounding one? (Vector type and design matter.)
- Will my data go into a registry?
Related: viral vectors in gene therapy, immune responses to gene therapy and somatic vs germline interventions.
Frequently asked questions
What is an off-target effect?
It is an unintended change at a DNA site other than the one a genome editing tool was aimed at. [1] Methods for finding and measuring such changes are still not standardized across studies. [2]
Does an off-target change always cause harm?
No source read here shows that. Whether a change matters depends on where it happens and in which cells. The FDA lists malignancy and impaired gene function as possible risks of undesirable genome changes. [3]
How long are gene therapy patients monitored?
The FDA's guidance describes up to 15 years for genome editing products and up to 5 years for AAV vectors, based on risk. [3]
Do all gene therapies carry cancer risk?
No. The FDA says vectors such as AAV that do not tend to integrate generally present lower risk of delayed adverse events, though product-specific changes matter. [3] Some integrating products have been linked to blood cancers. [4]
Is a gene therapy "permanent"?
The FDA notes gene therapy products are often designed to achieve effects through permanent or long-acting changes. [6] Durability differs by product and is still being followed.
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
How to read the evidence labels
Labels used on this page: approved medicine, promising but limited (early human data) and preclinical (cells or animals only). See how we label evidence.
Other long-term risks the FDA names
- Integration. Retroviral vectors (including lentiviral) and transposon elements work by an integration event. The FDA says this is generally not directed to specific sites, which raises the potential for disrupting critical genes or activating proto-oncogenes near the integration site, and thereby the risk of malignancies. [3]
- Genome editing. The FDA states that genome editing may produce undesirable changes in the genome, with risks including malignancies and impaired gene function. [3]
- Prolonged expression. Some products give long-lasting expression of the added gene, which is a separate concern. [3]
The FDA also notes that vectors that do not tend to integrate, including adeno-associated virus (AAV) vectors, generally present a lower risk of delayed adverse events, while saying that product-specific changes can alter that risk. [3]
A real example of a delayed risk
A related case for approved cell-based gene therapies: for the sickle cell product Lyfgenia the FDA says hematologic malignancy has occurred, a boxed warning is on the label, and patients should have lifelong monitoring for these malignancies. [5] This does not apply to every gene therapy, so each product has to be read on its own.
Safety note
References
- MedlinePlus Genetics (U.S. National Library of Medicine). What are genome editing and CRISPR-Cas9? Read 2026-10-22.
- Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges. Mol Ther Nucleic Acids. 2025. PMID 40777742. Abstract read 2026-10-22.
- U.S. Food and Drug Administration. Long Term Follow-up After Administration of Human Gene Therapy Products: Guidance for Industry (full text, PDF, January 2020). Read 2026-10-22.
- Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2024. PMID 39383458. Abstract read 2026-10-22.
- U.S. Food and Drug Administration. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. Press announcement, December 8, 2023. Read 2026-10-22.
- U.S. Food and Drug Administration. Long Term Follow-up After Administration of Human Gene Therapy Products (guidance page). Read 2026-10-22.
- U.S. Food and Drug Administration. Human Gene Therapy Products Incorporating Human Genome Editing (guidance page). Read 2026-10-22.
- Frangoul H, et al. Exagamglogene Autotemcel for Severe Sickle Cell Disease. N Engl J Med. 2024. PMID 38661449. Abstract read 2026-10-22.